Recurrent Wheezing in a 6-Year-Old
A 6-year-old boy is brought to your clinic for evaluation of recurrent wheezing. He has had 4 episodes of wheezing in the past year, each lasting about a week and responding to albuterol. He also has eczema and his mother has asthma. He is afebrile and has no nasal polyps. On exam, he has mild expiratory wheezing and nasal mucosa is pale and boggy. You consider a diagnosis of asthma but want to confirm and initiate therapy. The family is concerned about steroid side effects and asks if he really needs daily medication.
1. What is your diagnostic approach and initial treatment plan?
Read the worked answer
The clinical picture is consistent with asthma: recurrent wheezing, atopy (eczema, allergic rhinitis), family history, and response to albuterol. To confirm diagnosis, spirometry should be performed (if age-appropriate) and may show obstruction that reverses with bronchodilator. Consider allergy testing to aeroallergens.
Initial treatment: According to NHLBI guidelines, a child with mild persistent asthma (symptoms >2 days/week but not daily) should be started on a low-dose inhaled corticosteroid (ICS) as controller therapy. For mild intermittent, as-needed albuterol is sufficient. However, this child has had 4 episodes in a year, which may be mild persistent. Start low-dose ICS (e.g., fluticasone propionate 44 mcg, 2 puffs twice daily with spacer) and as-needed albuterol.
Address concerns: Explain that ICS are safe at low doses and much safer than frequent oral steroids. Use a spacer to reduce systemic absorption and side effects. Provide an asthma action plan and follow up in 4-6 weeks.
2. If the family refuses daily ICS, what alternative can you offer?
Read the worked answer
If the family refuses daily ICS, consider alternative strategies:
- Intermittent ICS: some guidelines allow intermittent ICS (e.g., at onset of respiratory illness) for children with mild persistent asthma, but evidence is less robust.
- Leukotriene receptor antagonist (montelukast) as an alternative controller, though less effective than ICS.
- Ensure as-needed albuterol is available and teach proper use.
- Emphasize regular follow-up and monitoring.
However, the best approach is to educate on the benefits of ICS and address concerns. Shared decision-making is key. If they still refuse, document and provide a written asthma action plan with clear instructions on when to seek care.